Published in PLoS One on March 26, 2013
Using a constraint-based regression method for relative quantification of somatic mutations in pyrosequencing signals: a case for NRAS analysis. Algorithms Mol Biol (2016) 0.75
Detection of BRAF, NRAS, KIT, GNAQ, GNA11 and MAP2K1/2 mutations in Russian melanoma patients using LNA PCR clamp and biochip analysis. Oncotarget (2017) 0.75
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol (2009) 23.08
The Catalogue of Somatic Mutations in Cancer (COSMIC). Curr Protoc Hum Genet (2008) 16.09
FLASH: fast length adjustment of short reads to improve genome assemblies. Bioinformatics (2011) 13.71
Melanoma. N Engl J Med (2006) 8.80
Sequence-specific error profile of Illumina sequencers. Nucleic Acids Res (2011) 6.88
Guilty as charged: B-RAF is a human oncogene. Cancer Cell (2004) 4.97
Dissecting the genomic complexity underlying medulloblastoma. Nature (2012) 4.77
Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol (2011) 3.66
NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing. Melanoma Res (2006) 3.32
NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin Cancer Res (2003) 2.72
Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis. Br J Dermatol (2011) 2.09
Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. J Clin Endocrinol Metab (2007) 1.95
Megapixel digital PCR. Nat Methods (2011) 1.94
Application of a BRAF pyrosequencing assay for mutation detection and copy number analysis in malignant melanoma. J Mol Diagn (2007) 1.85
Clinical correlates of NRAS and BRAF mutations in primary human melanoma. Clin Cancer Res (2010) 1.78
Polyclonality of BRAF mutations in primary melanoma and the selection of mutant alleles during progression. Br J Cancer (2011) 1.73
Absence of BRAF and NRAS mutations in uveal melanoma. Cancer Res (2003) 1.70
Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous syndromes: molecular diversity and associated phenotypic spectrum. Hum Mutat (2009) 1.49
The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis. PLoS One (2012) 1.34
B-RAF mutant alleles associated with Langerhans cell histiocytosis, a granulomatous pediatric disease. PLoS One (2012) 1.29
Pyrosequencing analysis for detection of a BRAFV600E mutation in an FNAB specimen of thyroid nodules. Diagn Mol Pathol (2008) 1.21
Detection of BRAFV600E mutation on fine needle aspiration specimens of thyroid nodule refines cyto-pathology diagnosis, especially in BRAF600E mutation-prevalent area. Clin Endocrinol (Oxf) (2006) 1.20
Functional characterization of a BRAF insertion mutant associated with pilocytic astrocytoma. Int J Cancer (2011) 1.17
Functional characterization of the T1799-1801del and A1799-1816ins BRAF mutations in papillary thyroid cancer. Cell Cycle (2007) 1.14
Detection of BRAF V600E mutations in skin metastases of malignant melanoma by monoclonal antibody VE1. J Am Acad Dermatol (2012) 1.09
A new BRAF gene mutation detected in a case of a solid variant of papillary thyroid carcinoma. Hum Pathol (2005) 1.04
Lack of BRAF mutations in Spitz nevi. J Invest Dermatol (2004) 1.04
The oncogenic B-raf V599E mutation occurs more frequently in melanomas at sun-protected body sites. Int J Oncol (2006) 1.01
Mutational patterns and novel mutations of the BRAF gene in a large cohort of Korean patients with papillary thyroid carcinoma. Thyroid (2012) 0.99
Pre-invasive ovarian mucinous tumors are characterized by CDKN2A and RAS pathway aberrations. Clin Cancer Res (2012) 0.99
A novel complex BRAF mutation detected in a solid variant of papillary thyroid carcinoma. Endocr Pathol (2009) 0.93
Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF(V599lns)). Clin Endocrinol (Oxf) (2006) 0.93
BRAF mutations in thyroid tumors from an ethnically diverse group. Hered Cancer Clin Pract (2012) 0.92
Absence of BRAF, NRAS, KRAS, HRAS mutations, and RET/PTC gene rearrangements distinguishes dominant nodules in Hashimoto thyroiditis from papillary thyroid carcinomas. Endocr Pathol (2010) 0.91
Functional characterization of the novel BRAF complex mutation, BRAF(V600delinsYM) , identified in papillary thyroid carcinoma. Int J Cancer (2012) 0.89
Mutational analysis of the BRAF gene in transitional cell carcinoma of the bladder. Int J Biol Markers (2009) 0.88
BRAF mutations distinguish anorectal from cutaneous melanoma at the molecular level. Gastroenterology (2004) 0.87
B-raf exon 15 mutations are common in primary melanoma resection specimens but not associated with clinical outcome. Oncology (2004) 0.84
Preponderance of the oncogenic V599E and V599K mutations in B-raf kinase domain is enhanced in melanoma cutaneous/subcutaneous metastases. BMC Cancer (2005) 0.83
Characterization of a novel complex BRAF mutation in a follicular variant papillary thyroid carcinoma. Eur J Endocrinol (2008) 0.81
Low prevalence of RAS-RAF-activating mutations in Spitz melanocytic nevi compared with other melanocytic lesions. J Cutan Pathol (2007) 0.78
International network of cancer genome projects. Nature (2010) 20.35
The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol (2010) 7.08
Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature (2011) 6.14
Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell (2012) 6.07
An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell (2008) 5.47
Dissecting the genomic complexity underlying medulloblastoma. Nature (2012) 4.77
Cdkn1a deletion improves stem cell function and lifespan of mice with dysfunctional telomeres without accelerating cancer formation. Nat Genet (2006) 4.43
Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification. J Clin Oncol (2006) 4.35
The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival. J Clin Oncol (2012) 4.30
Promiscuous gene expression in thymic epithelial cells is regulated at multiple levels. J Exp Med (2005) 4.06
Transient colocalization of X-inactivation centres accompanies the initiation of X inactivation. Nat Cell Biol (2006) 3.66
Primary malignant hepatic epithelioid hemangioendothelioma: a comprehensive review of the literature with emphasis on the surgical therapy. Cancer (2006) 3.16
Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer. Cancer Cell (2013) 3.08
Acute myeloid leukemias with reciprocal rearrangements can be distinguished by specific gene expression profiles. Proc Natl Acad Sci U S A (2002) 3.05
Recruitment and activation of a lipid kinase by hepatitis C virus NS5A is essential for integrity of the membranous replication compartment. Cell Host Microbe (2011) 3.05
MicroRNA gene expression profile of hepatitis C virus-associated hepatocellular carcinoma. Hepatology (2008) 3.00
Most pancreatic cancer resections are R1 resections. Ann Surg Oncol (2008) 2.79
RAGE signaling sustains inflammation and promotes tumor development. J Exp Med (2008) 2.51
Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat Genet (2013) 2.42
Group testing for pathway analysis improves comparability of different microarray datasets. Bioinformatics (2006) 2.37
Cross-platform analysis of cancer microarray data improves gene expression based classification of phenotypes. BMC Bioinformatics (2005) 2.36
Targeting the BRAF V600E mutation in multiple myeloma. Cancer Discov (2013) 2.32
Argonaute--a database for gene regulation by mammalian microRNAs. Nucleic Acids Res (2006) 2.26
Medullary epithelial cells of the human thymus express a highly diverse selection of tissue-specific genes colocalized in chromosomal clusters. J Exp Med (2004) 2.23
Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy. Cancer Res (2011) 2.08
Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing. Nat Genet (2012) 2.07
Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology (2006) 2.05
Exonuclease-1 deletion impairs DNA damage signaling and prolongs lifespan of telomere-dysfunctional mice. Cell (2007) 1.96
CD95-ligand on peripheral myeloid cells activates Syk kinase to trigger their recruitment to the inflammatory site. Immunity (2010) 1.91
Loss of the abundant nuclear non-coding RNA MALAT1 is compatible with life and development. RNA Biol (2012) 1.90
A Direct in vivo RNAi screen identifies MKK4 as a key regulator of liver regeneration. Cell (2013) 1.86
Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. J Thorac Oncol (2010) 1.85
Cyclooxygenase-2 inhibition induces apoptosis signaling via death receptors and mitochondria in hepatocellular carcinoma. Cancer Res (2006) 1.82
Critical role of the disintegrin metalloprotease ADAM17 for intestinal inflammation and regeneration in mice. J Exp Med (2010) 1.80
CCM2 mediates death signaling by the TrkA receptor tyrosine kinase. Neuron (2009) 1.79
K25 (K25irs1), K26 (K25irs2), K27 (K25irs3), and K28 (K25irs4) represent the type I inner root sheath keratins of the human hair follicle. J Invest Dermatol (2006) 1.72
Differential pattern of lipid droplet-associated proteins and de novo perilipin expression in hepatocyte steatogenesis. Hepatology (2008) 1.68
Hepatic NF-kappa B essential modulator deficiency prevents obesity-induced insulin resistance but synergizes with high-fat feeding in tumorigenesis. Proc Natl Acad Sci U S A (2008) 1.64
Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas. Genome Biol (2008) 1.64
Disruption of Trp53 in livers of mice induces formation of carcinomas with bilineal differentiation. Gastroenterology (2012) 1.63
Prediction of clinical outcome and biological characterization of neuroblastoma by expression profiling. Oncogene (2005) 1.62
Etiology-dependent molecular mechanisms in human hepatocarcinogenesis. Hepatology (2008) 1.62
Yes-associated protein up-regulates Jagged-1 and activates the Notch pathway in human hepatocellular carcinoma. Gastroenterology (2013) 1.58
Stimulation of the calcium-sensing receptor stabilizes the podocyte cytoskeleton, improves cell survival, and reduces toxin-induced glomerulosclerosis. Kidney Int (2011) 1.57
Strategies for hepatocellular carcinoma therapy and diagnostics: lessons learned from high throughput and profiling approaches. Hepatology (2011) 1.57
Quality management and accreditation of research tissue banks: experience of the National Center for Tumor Diseases (NCT) Heidelberg. Virchows Arch (2010) 1.55
Temporal transcriptomic analysis of the Listeria monocytogenes EGD-e sigmaB regulon. BMC Microbiol (2008) 1.54
Tumor-infiltrating lymphocytes in colorectal tumors display a diversity of T cell receptor sequences that differ from the T cells in adjacent mucosal tissue. Cancer Immunol Immunother (2013) 1.53
Genome-wide transcriptional analysis of the human cell cycle identifies genes differentially regulated in normal and cancer cells. Proc Natl Acad Sci U S A (2008) 1.53
Radiopharmaceutical therapy of patients with metastasized melanoma with the melanin-binding benzamide 131I-BA52. J Nucl Med (2013) 1.53
Methanobactin reverses acute liver failure in a rat model of Wilson disease. J Clin Invest (2016) 1.52
A highly standardized, robust, and cost-effective method for genome-wide transcriptome analysis of peripheral blood applicable to large-scale clinical trials. Genomics (2006) 1.51
Molecular profiling of human hepatocellular carcinoma defines mutually exclusive interferon regulation and insulin-like growth factor II overexpression. Cancer Res (2004) 1.50
Comparison of normalization methods for Illumina BeadChip HumanHT-12 v3. BMC Genomics (2010) 1.50
Protumorigenic overexpression of stathmin/Op18 by gain-of-function mutation in p53 in human hepatocarcinogenesis. Hepatology (2007) 1.48
Factors influencing pain intensity during topical photodynamic therapy of complete cosmetic units for actinic keratoses. J Am Acad Dermatol (2010) 1.48
High salt intake causes adverse fetal programming--vascular effects beyond blood pressure. Nephrol Dial Transplant (2012) 1.46
Seromic profiling of ovarian and pancreatic cancer. Proc Natl Acad Sci U S A (2010) 1.46
EGFR mutation detection in NSCLC--assessment of diagnostic application and recommendations of the German Panel for Mutation Testing in NSCLC. Virchows Arch (2010) 1.45
Overexpression of human Dickkopf-1, an antagonist of wingless/WNT signaling, in human hepatoblastomas and Wilms' tumors. Lab Invest (2003) 1.45
Liver fibrosis induced by hepatic overexpression of PDGF-B in transgenic mice. J Hepatol (2006) 1.45
The role of the pathologist in tissue banking: European Consensus Expert Group Report. Virchows Arch (2010) 1.44
Iron metabolism and the role of HFE gene polymorphisms in Wilson disease. Liver Int (2011) 1.44
Prognostic impact of gene expression-based classification for neuroblastoma. J Clin Oncol (2010) 1.43
Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma. BMC Cancer (2010) 1.42
Occult cytomegalovirus cholangitis as a potential cause of cholestatic complications after orthotopic liver transplantation? A study of cytomegalovirus DNA in bile. Liver Transpl (2013) 1.42
Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer. J Clin Oncol (2006) 1.41
Noncompaction myocardium in association with type Ib glycogen storage disease. Pathol Res Pract (2012) 1.41
Resistance of keratinocytes to TGFbeta-mediated growth restriction and apoptosis induction accelerates re-epithelialization in skin wounds. J Cell Sci (2002) 1.41
Regulation of DMBT1 via NOD2 and TLR4 in intestinal epithelial cells modulates bacterial recognition and invasion. J Immunol (2007) 1.40
Natural killer cells are scarce in colorectal carcinoma tissue despite high levels of chemokines and cytokines. Clin Cancer Res (2011) 1.40
Genome-wide association-, replication-, and neuroimaging study implicates HOMER1 in the etiology of major depression. Biol Psychiatry (2010) 1.39
Screening for Helicobacter pylori in Idiopathic Pulmonary Fibrosis Lung Biopsies. Respiration (2015) 1.39
Serum versus intrahepatic HCV RNA and liver histology. Hepatology (2002) 1.39
Oligonucleotide array-based comparative genomic hybridization (aCGH) of 90 neuroblastomas reveals aberration patterns closely associated with relapse pattern and outcome. Genes Chromosomes Cancer (2006) 1.38
Gene expression pattern in biomechanically stretched cardiomyocytes: evidence for a stretch-specific gene program. Hypertension (2007) 1.38
Microarray data warehouse allowing for inclusion of experiment annotations in statistical analysis. Bioinformatics (2002) 1.37
Decentral gene expression analysis for ER+/Her2- breast cancer: results of a proficiency testing program for the EndoPredict assay. Virchows Arch (2012) 1.37
Molecular diagnostic profiling of lung cancer specimens with a semiconductor-based massive parallel sequencing approach: feasibility, costs, and performance compared with conventional sequencing. J Mol Diagn (2013) 1.37
Proapoptotic and antiproliferative potential of selective cyclooxygenase-2 inhibitors in human liver tumor cells. Hepatology (2002) 1.35
p53 deletion impairs clearance of chromosomal-instable stem cells in aging telomere-dysfunctional mice. Nat Genet (2009) 1.33
Decoy receptor 3 is a prognostic factor in renal cell cancer. Neoplasia (2008) 1.33
Microarray-based approach identifies microRNAs and their target functional patterns in polycystic kidney disease. BMC Genomics (2008) 1.32
Antiviral activity and hepatoprotection by heme oxygenase-1 in hepatitis B virus infection. Gastroenterology (2007) 1.32
Autocrine insulin-like growth factor-II stimulation of tumor cell migration is a progression step in human hepatocarcinogenesis. Hepatology (2008) 1.30
Lipid droplet-associated PAT-proteins show frequent and differential expression in neoplastic steatogenesis. Mod Pathol (2010) 1.29
Methylome analysis and integrative profiling of human HCCs identify novel protumorigenic factors. Hepatology (2012) 1.29
Neoadjuvant chemoradiation with Gemcitabine for locally advanced pancreatic cancer. Radiat Oncol (2012) 1.28
S100A8 and S100A9 are novel nuclear factor kappa B target genes during malignant progression of murine and human liver carcinogenesis. Hepatology (2009) 1.28
Liver cancer biopsy--back to the future?! Hepatology (2015) 1.26
Posttranscriptional destabilization of the liver-specific long noncoding RNA HULC by the IGF2 mRNA-binding protein 1 (IGF2BP1). Hepatology (2013) 1.26
Oncogenic and tumor suppressive roles of polo-like kinases in human hepatocellular carcinoma. Hepatology (2010) 1.26
Oxidative damage is increased in human liver tissue adjacent to hepatocellular carcinoma. Hepatology (2004) 1.24
Coordinated expression of stathmin family members by far upstream sequence element-binding protein-1 increases motility in non-small cell lung cancer. Cancer Res (2009) 1.23
Calcification of coronary intima and media: immunohistochemistry, backscatter imaging, and x-ray analysis in renal and nonrenal patients. Clin J Am Soc Nephrol (2006) 1.22